Compounds > isoxazoles
Page last updated: 2024-08-21

isoxazoles and Apoplexy

isoxazoles has been researched along with Apoplexy in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's2 (28.57)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Demyanenko, SV; Uzdensky, A1
Jin, K; Sun, F; Uteshev, VV1
Horvath, R; Janszky, J; Komoly, S1
Hashimoto, K; Takahashi, Y; Tsuji, S1
Couzin, J1
Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J1

Reviews

1 review(s) available for isoxazoles and Apoplexy

ArticleYear
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
    Ideggyogyaszati szemle, 2015, May-30, Volume: 68, Issue:5-6

    Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug Approval; Drug Prescriptions; Electroencephalography; Encephalitis; Epilepsies, Partial; Humans; Hungary; Isoxazoles; Levetiracetam; Magnetic Resonance Imaging; Medication Adherence; Obesity; Phenytoin; Piracetam; Risk Assessment; Risk Factors; Seizures; Stroke; Weight Loss; Young Adult; Zonisamide

2015

Other Studies

6 other study(ies) available for isoxazoles and Apoplexy

ArticleYear
LIM kinase inhibitor T56-LIMKi protects mouse brain from photothrombotic stroke.
    Brain injury, 2021, 03-21, Volume: 35, Issue:4

    Topics: Animals; Benzamides; Brain; Brain Ischemia; Disease Models, Animal; Isoxazoles; Lim Kinases; Mice; Stroke

2021
A type-II positive allosteric modulator of α7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Behavior, Animal; Brain Ischemia; Disease Models, Animal; Isoxazoles; Male; Motor Activity; Neuroprotective Agents; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Stroke

2013
Successful use of zonisamide for central poststroke pain.
    The journal of pain, 2004, Volume: 5, Issue:3

    Topics: Anticonvulsants; Calcium Channel Blockers; Calcium Channels, T-Type; Cerebral Infarction; Diabetes Complications; gamma-Aminobutyric Acid; Humans; Isoxazoles; Magnetic Resonance Imaging; Male; Middle Aged; Pain; Stroke; Zonisamide

2004
Could Bextra increase heart risks too?
    Health news (Waltham, Mass.), 2004, Volume: 10, Issue:12

    Topics: Coronary Artery Bypass; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Health Status; Humans; Isoxazoles; Myocardial Infarction; Stroke; Sulfonamides

2004
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713

    Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States

2008